LeadArtis is currently funded by Growth Factor Biocapital, Bionexum Ventures, SODENA and Clave Capital and other angel investors as well as with non-dilutive grants.
R&D activities, facilities and equipment have been co-financed by the Spanish Ministry of Science and Innovation (Torres Quevedo Programs), RETOS Collaboration programs; CDTI, the RIS3 innovation program from the Comunidad de Madrid regional initiative; and by the 7th European Framework Program (FP7). Additionally, we have received support by the Genoma España Foundation and by the Carlos III Health Institute.
LeadArtis news imageLeadArtis news image

Latest News

SARS-CoV-2 Spike Trimerbody could represent a therapeutic option for COVID-19.

We are glad to report that in a recently published EMBO Journal...

"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.


Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital...